Senseonics Holdings Inc. ( (SENS) ) has released its Q3 earnings. Here is a breakdown of the information Senseonics Holdings Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Senseonics Holdings, Inc. is a medical technology company specializing in the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for individuals with diabetes. The company is known for its innovative Eversense CGM systems, which offer extended wear durations compared to traditional glucose monitors.
In its latest earnings report, Senseonics Holdings, Inc. announced a significant increase in revenue for the third quarter of 2025, reaching $8.1 million, which marks a 90% growth compared to the same period in the previous year. This growth was largely driven by a 160% increase in new patient starts in the U.S. The company is also preparing to transition the commercial responsibility of its Eversense CGM system back from Ascensia Diabetes Care to Senseonics.
Key financial highlights include a gross profit of $3.5 million for the quarter, a significant improvement from a gross loss in the previous year, attributed to favorable product margins and the launch of the Eversense 365-day product. Research and development expenses decreased due to the completion of clinical trials, while selling, general, and administrative expenses rose due to increased marketing efforts. Despite a net loss of $19.5 million, this represents an improvement from the previous year’s loss, driven by better gross profit margins and reduced R&D costs.
Looking ahead, Senseonics anticipates continued revenue growth with the commercialization of Eversense 365, expecting full-year 2025 global net revenue to reach approximately $35 million. The company plans to expand its patient base and improve gross margins, with a focus on launching Eversense 365 in the EU and advancing its next-generation Gemini product. Senseonics remains committed to enhancing its market presence and driving further adoption of its innovative CGM systems.